Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survivin mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Vrije Universiteit Brussel
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
The survivin mRNA vaccine is an experimental therapeutic cancer vaccine designed to treat multiple myeloma (MM) by targeting the tumor-associated antigen survivin (BIRC5). The specific formulation described in recent research utilizes the "Galsome" platform, which consists of lipid nanoparticles (LNPs) containing mRNA encoding survivin and the adjuvant alpha-galactosylceramide (α-GalCer). This dual-action approach is intended to activate both survivin-specific CD8+ T cells and invariant natural killer T (iNKT) cells via the CD1d pathway. While preclinical studies in mouse models have shown a reduction in MM cell levels in the bone marrow and spleen, researchers have observed that survivin expression in activated T cells may lead to unintended reduction of the effector cell populations following boost vaccinations, suggesting a need for careful antigen selection or combination therapies.
- Other names
- mRNA-survivin vaccinesurvivin-encoding mRNA vaccineGalsome-survivin mRNA vaccine
02
Targets
BIRC5 (Survivin)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on survivin mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survivin mRNA vaccine.